In a nutshell This phase 1 clinical trial will test the maximum dose of chimeric antigen receptor (CAR) T-cells in treating advanced lymphoid leukemia and lymphoma. The primary outcome will be measured by the maximum tolerated dose. This trial is being conducted at the University of Texas MD Anderson Cancer Center in Houston, Texas. The details...
Read More
In a nutshell This trial looked at therapy that activates the immune system to kill cancerous tumors in patients with extensive stage small cell lung cancer (ES-CLC). The authors concluded pembrolizumab (Keytruda) is tolerable and a promising treatment for patients with heavily treated ES-SCLC. Some background Extensive-stage small cell lung...
Read More
In a nutshell This phase 1/2 clinical trial will test the effectiveness of chimeric antigen receptor (CAR) T-cells in treating chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and non-Hodgkin’s lymphoma (NHL). The primary outcome will be measured by the response to treatment, overall survival, and the maximum tolerated...
Read More
In a nutshell This phase 2 clinical trial will test the effectiveness of axicabtagene ciloleucel (KTE-C19) in treating relapsed or refractory (unresponsive to treatment) indolent non-Hodgkin’s lymphoma (iNHL). The primary outcome will be measured by the response rate. The details Axicabtagene ciloleucel is a chimeric antigen...
Read More
In a nutshell This phase 2 clinical trial will determine the effectiveness of denintuzumab mafodotin (SGN-CD19A) with RICE chemotherapy in patients with relapsed or refractory (unresponsive to treatment) diffuse large B-cell lymphoma (DLBCL) or stage 3b follicular lymphoma (FL). The primary outcome will be measured by the complete remission...
Read More
In a nutshell This trial examined whether altering the recommended dose of chemotherapy drugs during treatment was beneficial to patients. This trial concluded that altering doses of paclitaxel (Taxol) during chemotherapy could be beneficial to reduce neuropathy in patients with advanced non-small-cell lung cancer. Some...
Read More
In a nutshell This study compared the side effects and outcome of two drug regimens in women with high-risk node-positive breast cancer (BC). Both treatment regimens were found to have similar survival outcomes. Some background Standard treatment in node positive BC (cancer that has spread to the lymph nodes) consists of two categories of...
Read More
In a nutshell This study investigated whether exercise was associated with a reduction in the risk of cardiovascular disease (CVD) in patients with non-metastatic breast cancer (BC). Exercise was found to be linked to a significant reduction in the risk of CVD for this patient group. Some background CVD is a leading cause of death among women with...
Read MoreIn a nutshell This study investigated ovarian function recovery (OFR) after chemotherapy-induced amenorrhea (absence of menstruation) in women aged 40-49 after 2 years of aromatase inhibitor (AI) therapy. The study concluded that a large number of women with chemotherapy-induced amenorrhea recover ovarian function during AI therapy. Some...
Read MoreIn a nutshell This study investigated the long term risk of axillary (underarm lymph node) recurrence in breast cancer (BC) patients who were not treated with axillary lymph node dissection (ALND) following a negative sentinel node biopsy (SNB) result. The study concluded that the risk of axillary recurrence after 10 years was lower than expected after...
Read More
In a nutshell This study investigated the impact of whole breast radiation therapy (WBRT) and accelerated partial breast irradiation (APBI) on the severity of post-treatment side effects and quality of life. This study concluded that both forms of radiation therapy (RT) show similar survival benefits and similar quality of life in early-stage breast...
Read More
In a nutshell This study determined whether certain risk factors predicted outcomes in primary refractory Hodgkin lymphoma. The authors concluded that risk factors such as stage IV disease and cancer activity seen on imaging predicted worse overall outcomes. Some background Refractory disease Hodgkin lymphoma patients are those who are...
Read More
